Why Eli Lilly's Q2 Results May Trigger a Catch-Up Rally

Eli Lilly (LLY) is scheduled to report second quarter earnings on Thursday, before the market open. The stock was up about 0.5% through the trading week as of this afternoon as the broader market recovered following last week’s jobs report.
The pharmaceutical company has seen big wins in recent years from its tirzepatide products, which include Mounjaro and Zepbound.
In the first quarter, Mounjaro contributed nearly $4 billion in revenue, increasing over 100% from the previous year, while Zepbound brought in $2.3 billion, nearly quadrupling from the $517 million it did a year ago. Combined, those two drugs contributed nearly 50% of Eli Lilly’s growth from the year before.
Now, investors are anticipating that Zepbound may gain Medicare coverage for weight management under a government pilot program, which would significantly expand the drug’s market access. Without insurance, Zepbound can cost over $700 per month, making it inaccessible to many. Currently, Zepbound is only Medicare-approved to treat obstructive sleep apnea in obese adults.
However, Medicare is also investigating Wegovy and Ozempic, two drugs from Novo Nordisk (NVO) that compete with Lilly’s weight-loss drugs. Still, gaining Medicare coverage would undoubtedly boost sales for Lilly and likely be seen as a major tailwind for investors.
Lilly also has an intriguing pipeline that includes an oral GLP-1 drug called Orforglipron. The company announced positive Phase 3 results in April, making it the first oral small molecule GLP-1 receptor agonist to complete the critical step. Indications for weight loss and type 2 diabetes are expected later this year and next year.
Analysts expect sales could top $10 billion by 2030.
Analysts expect Lilly will post earnings per share (EPS) of $5.60 on $14.7 billion in revenue, according to TradingView. Last year, EPS came in at $3.92 on $11.3 billion in revenue. That would also represent an increase from last quarter’s EPS of $3.34 on $12.73 billion in revenue.
Analysts are mostly bullish on the stock, with 25 “strong buy” and “buy” ratings, three “hold ratings,” one “sell” rating, and one “strong sell” rating. The average one-year price target on the stock is $989, representing a 29% increase from today’s $767 stock price.
Eli Lilly traded with an implied volatility rank (IVR) of 39.2 today, Aug. 5. That means volatility in the stock is below average compared with the past 12 months of trading. The options market expects an implied move of +/- 47.14 points, or 6.15% of today’s stock price.
The stock is up about 13% since its April lows, which lags behind the S&P 500’s 30% gain over the same period. It’s trading below its 50- and 200-day simple moving averages (SMA), although it has put in a series of higher lows since April. The underperformance since April vs. the S&P 500 may allow for a catch-up trade if the results impress.

Thomas Westwater, a tastylive financial writer and analyst, has eight years of markets and trading experience. @fxwestwater
For live daily programming, market news and commentary, visit tastylive or the YouTube channels tastylive (for options traders), and tastyliveTrending for stocks, futures, forex & macro.
Trade with a better broker,open a tastytrade account today. tastylive, Inc. and tastytrade, Inc. are separate but affiliated companies.
Options involve risk and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options before deciding to invest in options.
tastylive content is created, produced, and provided solely by tastylive, Inc. (“tastylive”) and is for informational and educational purposes only. It is not, nor is it intended to be, trading or investment advice or a recommendation that any security, futures contract, digital asset, other product, transaction, or investment strategy is suitable for any person. Trading securities, futures products, and digital assets involve risk and may result in a loss greater than the original amount invested. tastylive, through its content, financial programming or otherwise, does not provide investment or financial advice or make investment recommendations. Investment information provided may not be appropriate for all investors and is provided without respect to individual investor financial sophistication, financial situation, investing time horizon or risk tolerance. tastylive is not in the business of transacting securities trades, nor does it direct client commodity accounts or give commodity trading advice tailored to any particular client’s situation or investment objectives. Supporting documentation for any claims (including claims made on behalf of options programs), comparisons, statistics, or other technical data, if applicable, will be supplied upon request. tastylive is not a licensed financial adviser, registered investment adviser, or a registered broker-dealer. Options, futures, and futures options are not suitable for all investors. Prior to trading securities, options, futures, or futures options, please read the applicable risk disclosures, including, but not limited to, the Characteristics and Risks of Standardized Options Disclosure and the Futures and Exchange-Traded Options Risk Disclosure found on tastytrade.com/disclosures.
tastytrade, Inc. ("tastytrade”) is a registered broker-dealer and member of FINRA, NFA, and SIPC. tastytrade was previously known as tastyworks, Inc. (“tastyworks”). tastytrade offers self-directed brokerage accounts to its customers. tastytrade does not give financial or trading advice, nor does it make investment recommendations. You alone are responsible for making your investment and trading decisions and for evaluating the merits and risks associated with the use of tastytrade’s systems, services or products. tastytrade is a wholly-owned subsidiary of tastylive, Inc.
tastytrade has entered into a Marketing Agreement with tastylive (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade. tastytrade and Marketing Agent are separate entities with their own products and services. tastylive is the parent company of tastytrade.
tastyfx, LLC (“tastyfx”) is a Commodity Futures Trading Commission (“CFTC”) registered Retail Foreign Exchange Dealer (RFED) and Introducing Broker (IB) and Forex Dealer Member (FDM) of the National Futures Association (“NFA”) (NFA ID 0509630). Leveraged trading in foreign currency or off-exchange products on margin carries significant risk and may not be suitable for all investors. We advise you to carefully consider whether trading is appropriate for you based on your personal circumstances as you may lose more than you invest.
tastycrypto is provided solely by tasty Software Solutions, LLC. tasty Software Solutions, LLC is a separate but affiliate company of tastylive, Inc. Neither tastylive nor any of its affiliates are responsible for the products or services provided by tasty Software Solutions, LLC. Cryptocurrency trading is not suitable for all investors due to the number of risks involved. The value of any cryptocurrency, including digital assets pegged to fiat currency, commodities, or any other asset, may go to zero.
© copyright 2013 - 2025 tastylive, Inc. All Rights Reserved. Applicable portions of the Terms of Use on tastylive.com apply. Reproduction, adaptation, distribution, public display, exhibition for profit, or storage in any electronic storage media in whole or in part is prohibited under penalty of law, provided that you may download tastylive’s podcasts as necessary to view for personal use. tastylive was previously known as tastytrade, Inc. tastylive is a trademark/servicemark owned by tastylive, Inc.